Highlights from ASH

December 13, 2023

From 08th to 12th December 2023, ALAN attended the 65th ASH Annual Meeting and Exposition in San Diego (USA).

Reports on sessions

Latest treatment options for patients with relapsed, refractory or persistent AML

A comprehensive discussion on the available treatment options for acute myeloid leukemia (AML) and how to choose the most appropriate, unfolded during this educational session at ASH 2023. Dr Jacqueline Cloos from VU University Medical Center, Amsterdam, the Netherlands, discussed the challenges of categorising patients into different risk groups. The European Leukemia Network (ELN) risk classification that takes into account molecular and chromosomal abnormalities, was highlighted as an effective way to divide patients into favourable, intermediate, and adverse categories. Dr Cloos further underscored the clinical significance of measurable residual disease (MRD) and its pivotal role in treatment decisions, presenting evidence linking MRD negativity to improved outcomes. The presentation explored how and when to use various MRD assessment tools (quantitative real-time polymerase chain reaction [qRT-PCR], flow cytometry, next-generation sequencing, digital PCR) according to each patient’s risk classification and clinical picture. Important ongoing trials were discussed that aim to establish MRD as a substitute measure for treatment success and others that explore MRD-guided treatments. Dr Cloos concluded by highlighting the need for real-world evidence to complement the results from clinical trials and to demonstrate the value of MRD not just in the research setting.

The session continued with Dr Marion Subklewe from Ludwig-Maximilians-University Hospital, Munich, Germany, discussing the recent immunotherapy advancements for AML and their potential alongside established therapies to enhance MRD negativity and outcomes. The presentation covered various immunotherapies, such as antibody-drug conjugates, monoclonal antibodies, bispecifics and CAR T. Their challenges including identifying suitable target antigens and dealing with antigen escape- when tumor cells evolve to express fewer target antigens, reducing the ability of CAR T-cells to recognise and attack them effectively- were also discussed. Dr Subklewe concluded with a plea for reaching a consensus in assessing patient genetics, phenotype, and inflammatory signatures to tailor immunotherapy for individual AML patients and thus improve outcomes.

The session concluded with Dr Alison Walker from the Moffitt Cancer Center, Florida, USA, shifting into new treatments for patients who are relapse/refractory to initial therapies. Dr Walker explored factors that could be predictive of treatment failure, like the genetic mutation TP53, which has been linked to treatment resistance and those associated with positive responses (NPM1, IDH1, IDH2, DNMT3A mutations). Moreover, the importance of MRD assessment and how it can be a useful indicator of treatment response duration was noted. Dr Walker further explored the biological mechanisms behind resistance to venetoclax-based treatments seen in some patients. The speaker highlighted the scarcity of data for these patients who relapse during or after venetoclax plus hypomethylating agent therapy, emphasising the huge challenge in treatment and outcome improvement. Potential therapies for this patient group were then explored, including ongoing clinical trials, with novel combination therapies blocking more than one tumor target (e.g., BCL2, MCL1, menin) and immunotherapies like pivekimab sunirine (IMGN632) and magrolimab being highlighted as promising avenues. Nevertheless, Dr Walker stressed that relapse/refractory AML, regardless of initial therapy, remains an unmet therapeutic need and ongoing research to advance treatment options remains paramount.

What does this mean for patients?

Relapse or refractory AML remains an unmet therapeutic need. The session acknowledges the complexities involved in managing and treating this population. However, what stands out is the commitment to finding effective solutions for these patients with many novel combination therapies and immunotherapies being evaluated in clinical trials. Along with those, the current array of tools to assess MRD and to guide treatment decisions from the beginning based on each patient’s molecular and genetic abnormalities instils optimism for a more personalised approach that enhances patient outcomes.

The evolution of AML therapy: from tradition to innovation

In this educational session during ASH 2023, the evolution of therapies for acute myeloid leukemia (AML) was discussed along with how it has transformed the current standard of care. Dr Christoph Röllig, Universitätsklinikum TU Dresden, Germany, opened the discussion with a historical perspective on the use of intensive chemotherapy in AML. He highlighted that today’s real-world data demonstrate that intensive chemotherapy leads to significantly increased survival and longer freedom from disease. The session further delved into the comparison of intensive chemotherapy and newer agents like azacitidine (AZA) plus venetoclax (VEN). The superiority between these approaches is yet to be determined, pending the results of ongoing clinical trials. Dr Röllig presented evidence from trials on novel drugs like gemtuzumab ozogamicin, midostaurin, and quizartinib, which when combined with intensive chemotherapy show positive impacts on survival outcomes in specific AML patient groups. Exploring the future of intensive chemotherapy, Dr Röllig envisioned a future where novel agents complement or replace components of intensive chemotherapy, allowing for personalised and more effective treatments, guided by patient risk classification.

Dr Tara Lin from The University of Kansas Medical Center, Kansas, USA, focused on the combination of AZA and VEN for older and unfit patients, specifically discussing the VIALE-A trial. Updated data from this pioneering clinical trial demonstrate a consistent survival advantage over time for patients who received the AZA-VEN combination. This combination proves valuable, extending treatment options to elderly patients previously deemed unfit for therapy. The speaker discussed the advantages of a community and academic partnership in treating AML patients, emphasising the collaborative efforts required for comprehensive care, diagnostic testing, and access to clinical trials. The presentation delved into several retrospective studies examining the use of AZA-VEN in different patient populations, such as those with favorable risk cytogenetics or specific genetic mutations. The studies suggested potential benefits for certain subgroups but emphasised the need for prospective, randomised trials. Limited data on using AZA-VEN as a pre-transplant regimen was also discussed.

Concluding the session, Dr Justin Watts from the University of Miami Miller School of Medicine, Florida, USA, discussed the future of AML therapy with a focus on understanding mechanisms of VEN resistance and exploring targeted therapies for patients with specific genetic mutations (e.g., FLT3, TP53, IDH1/2). Dr Watts unraveled the intricacies of VEN resistance, outlining specific genetic mutations (e.g., FLT3, RAS, TP53, BAX) and cellular alterations contributing to it. Survival in AML is closely linked to specific mutations, with patients lacking FLT3, RAS, and TP53 mutations having better outcomes. With regards to targeted therapies, the speaker presented promising developments with IDH1 (ivosidenib) and IDH2 inhibitors (enasidenib) suggesting their potential addition to primary treatment along with VEN and AZA. For patients with FLT3 mutations, combining VEN with FLT3 blockers showed promise, especially in younger patients aiming for a transplant. Menin blockers, which could be a game-changer by targeting certain genetic mutations (MPM1, MLL rearrangements) were also discussed. Challenges remain, particularly in addressing treatment decisions in patients with RAS mutations or TP53 alterations due to mixed successes in clinical trials.

What does this mean for patients?

Overall, these advancements bring optimism and expand treatment options for individuals with AML. Increased survival benefits with intensive chemotherapy have now been confirmed in the real-world setting and newer combinations like AZA plus VEN, have shown promising outcomes particularly for older and unfit patients. Ongoing trials aim to determine the best approach, offering hope for more personalised and effective treatments. The discussion and current research on targeted therapies for specific genetic mutations signals a future with more tailored therapies and improved outcomes for AML patients.

Navigating challenges in AYA ALL: Insights from ASH 2023

The management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA) poses a unique challenge, given their age range of 15–39 years, placing them at the crossroads of pediatric and adult oncology. Despite improved outcomes in pediatric cases, AYA patients show less progress leading to what is commonly known as the “AYA age gap”. This ASH 2023 educational session explored treatment approaches and distinctions between AYA and pediatric patients with ALL and explored ways of enhancing outcomes within this patient group.

Dr John Molina from Taussig Cancer Institute, Ohio, USA, initiated the discussion by critically examining outcomes for AYA patients with B-cell ALL undergoing treatment with conventional pediatric or “pediatric-inspired” regimens as initial therapy. Critical evaluation of clinical trials showed that treatment location (adult or pediatric facilities) significantly impacted patient survival rates, with pediatric-inspired regimens leading to superior outcomes and emerging as a global standard for AYA ALL (CalGB10403 or Dana-Farber regimens). The integration of immunotherapies into established chemotherapy protocols, and the changing landscape of using hematopoietic stem cell transplant (HSCT) as a consolidative therapy for AYA patients who achieve a first complete remission were also discussed. Dr Molina concluded by stressing the importance of considering long-term toxicities, fertility concerns, and quality of life in AYA patients, along with employing next-generation sequencing (NGS) for the assessment of measurable residual disease (MRD) to guide treatment.

Dr Tamara Miller from the Children’s Healthcare of Atlanta, Georgia, USA, discussed the biological differences between pediatric and AYA patients, including variations in cancer biology, response to chemotherapy and the prevalence of specific genetic abnormalities. AYA patients may experience higher toxicities and lower tolerance to chemotherapy compared to younger patients. This is attributed to physiological changes during the AYA period, resulting in increased rates of adverse events and potential challenges in adhering to treatment. The need for increased care during this critical age for developing independence and identity, along with factors like fertility concerns, financial burdens, and disruptions in relationships, were highlighted as key challenges in AYA patients that could potentially influence adherence to therapy and increase the risk of relapse. Additionally, AYA patients seem less likely to enroll in clinical trials, with various barriers including the lack of open trials for this age group, mismatched age requirements, and competing priorities such as school and work, contributing to this.

Dr Emily Curran, University of Cincinnati, Ohio, USA, concluded the session by highlighting novel therapeutic advancements and challenges in AYA patients. Recognising challenges posed by adverse cancer biology prevalent in some AYA cases (e.g., Philadelphia chromosome[pH]-like ALL, KMT2A rearranged ALL), Dr Duran discussed ongoing investigations, including kinase inhibitors for pH-like ALL and menin inhibition for KMT2A ALL. Dr Curan mentioned the lack of immunotherapy options for T-cell ALL, unlike B-cell ALL, emphasised ongoing trials exploring BCL2 and BCLXL blockade and highlighted early promise of CAR T-cell therapy in this patient group. The talk addressed the psychosocial factors affecting AYA patients, including treatment adherence issues, health insurance, and clinical trial enrollment. The use of technology, such as text message reminders, as a potential strategy to improve adherence and clinical trial enrollment were also noted.

What does this mean for patients?

The session underscored the unmet needs of AYA patients with ALL, stressing the necessity for interventions addressing the unique cancer biology, genetics, and psychosocial aspects. Comprehensive strategies targeting biological, treatment-related, psychosocial, and enrollment challenges are crucial to enhance outcomes and advance clinical knowledge in this patient group. Bridging the “AYA age gap” remains an ongoing journey.

How to choose between stem cell transplantation and CAR T-cell therapy in pediatric ALL

An educational session took place at ASH 2023 focusing on the treatment of pediatric acute lymphoblastic leukemia (ALL). Most children with ALL achieve long-term remission through chemotherapy alone, but some relapse or remain refractory, leading to the need for additional therapies. For these high-risk patients, two key treatments have shown great promise: hematopoietic stem cell transplantation (HSCT) and CAR T-cell therapy. HSCT has a long-established track record of favorable survival rates, whilst CAR T has shown transformative potential with stellar remission rates. To date, the decision between HSCT and CAR T is primarily driven by physician judgment and institutional preference. The session explored the criteria used to guide this choice with Dr Nirali Shah from the National Institutes of Health, outlining individual patient risk factors, prior complications, organ functions, donor availability, institutional expertise, and access to cellular therapy as key considerations. Moreover, Dr Shah discussed delayed toxicities following CAR T, including effects on neurocognition and fertility and their management. She emphasised the need for research evaluating other late CAR T toxicities, including the monitoring for potential second tumors and future fertility.

Previously vital for chemotherapy-resistant cases, HSCT faces competition from CAR T-cell therapy. Dr Alice Bertaina from Stanford University, California, USA, further discussed the need to redefine the timing and use of HSCT in pediatric ALL. Dr Bertaina concluded that HSCT remains a crucial treatment for high-risk and relapse-refractory ALL patients and that choosing the right treatment involves considering various factors unique to each patient and the treatment center, beyond the reported literature. Proposing a future strategy, Dr Bertaina advocated for the integration of HSCT with CAR T in this high-risk population, tailored by specific patient risk factors. She further stressed the need to design clinical trials focused on finding biomarkers that could help guide this decision in this rare high-risk pediatric population to improve patient outcomes.

Dr Stephen Gosselk from St. Jude Children’s Research Hospital, Tennessee, USA, concluded the session by addressing the challenges of determining the optimal step after CAR T-cell therapy. He acknowledged the absence of a clear treatment algorithm for deciding which patients should undergo HSCT, whilst exploring ways to prevent relapse after CAR T in pediatric ALL. He also stated that the decision to proceed to HSCT involves the evaluation of multiple factors like, prior therapies, residual disease, genetic risk, conditioning regimens, as well as CAR T product characteristics. Dr Gosselk highlighted key findings indicating that achieving no residual disease, sustaining low levels of B-cells for six months, administering an optimal dose of the conditioning regimen, and ensuring a high number of circulating CAR T-cells post-infusion are pivotal indicators of favorable outcomes. In conclusion, the ongoing requirement for predictive biomarkers and prevention of CAR T relapse were highlighted. Acknowledging the need for additional research, the speaker emphasised the importance of improving CAR T products to minimise challenges associated with low persistence within the body or antigen escape- when tumor cells evolve to express fewer target antigens, reducing the ability of CAR T-cells to recognise and attack them effectively.

What does this mean for patients?

This educational session on pediatric ALL, instilled optimism regarding treatment options for high-risk patients facing relapse or unresponsiveness to chemotherapy. Beyond traditional HSCT, CAR T offers a valuable alternative, prompting the need to redefine criteria for choosing between the two. The speakers highlighted the ongoing establishment of these criteria, with residual disease, individual risks, prior therapies/toxicities, treatment availability, and center expertise being key considerations for decision-making. The importance of an integrated approach with both treatments used and of novel clinical trials investigating biomarkers to help guide treatment decisions were highlighted.

Fertility empowerment for hematologic cancer patients: Navigating challenges and options

Patients with hematologic cancers encounter a myriad of challenges when considering fertility preservation options. With the advent of innovative technologies and a heightened awareness of the importance of fertility preservation, numerous opportunities have emerged. Dr Erica Marsh from the University of Michigan, Michigan, USA, opened the session by reflecting on the current design of health systems, urging an understanding of who these systems include or exclude. The speaker provided definitions for key terms like inequality, equality, and equity, in the context of healthcare. The need for tools to address health disparities revolving around race, ethnicity, socioeconomic status, gender, age, mental health and historical discrimination was also highlighted. Connecting health disparities to infertility, Dr Marsh encouraged the understanding of patients through two key concepts: i) intersectionality, recognising individuals as multifaceted beings influenced by race, gender, reproductive status, occupation, and more; and ii) positionality, how our worldview is shaped by social and cultural influences, determining how we perceive and engage with the world.

Dr Alison Loren from the University of Pennsylvania, Pennsylvania, USA, continued the discussion by highlighting the emotional impact of infertility on cancer survivors and urging for early patient-doctor discussions even if immediate fertility preservation is not deemed feasible. Dr Loren addressed existing barriers that include provider discomfort, racial and socioeconomic biases, and insurance coverage issues. Fertility options for critically ill patients who cannot undergo standard procedures were also explored, with a focus on gonadotropin-releasing hormone analogs, which remain controversial and ovarian tissue cryopreservation. The speaker further emphasised the importance of ongoing fertility discussions post-therapy, revealing the risk of premature ovarian failure in survivors. Dr Loren concluded with a plea to hematologists to initiate fertility conversations, be aware of biases, establish connections with reproductive specialists, and consider legislative advocacy for better patient coverage.

Dr Mindy Christianson from the Cleveland Clinic, Cleveland, Ohio, USA, concluded the session by addressing surgical fertility preservation, emphasising ovarian tissue transplantation and introducing a novel technique called uterine suspension. Ovarian tissue cryopreservation, pioneered in 2000, has evolved, with over 200 reported live births. Standard practice involves removing one ovary for freezing and potential future transplantation. Various techniques exist for transplanting tissue, but there is no standardised best practice. The talk highlighted the challenges and success rates associated with different methods. Switching focus to uterine preservation after pelvic radiation, the speaker discussed uterine fixation, a surgical technique which involves moving the uterus out of the radiation field for protection. While still new, this approach shows promise in preserving fertility for cancer patients. The discussion concluded with tips for success in fertility preservation centers, emphasising the need for open communication between oncologists and fertility specialists. Building a patient-centered team that is well-versed in all pathways to parenthood, including in-vitro fertilization (IVF), egg donation, and gestational surrogacy, was stressed. Additionally, the importance of healthcare professionals being aware of financial considerations, hurdles, and state mandates for fertility coverage was highlighted.

What does this mean for patients?

This information empowers hematologic cancer patients to consider and address fertility concerns, urging early discussions with healthcare providers and reproductive specialists. The emotional impacts and barriers survivors face are slowly being acknowledged and together with the evolving techniques, from ovarian tissue transplantation to uterine preservation, they offer hope for improved fertility preservation. A patient-centric approach with open communication and good awareness of parenthood pathways from healthcare professionals are crucial for informed decision-making.

Advancing patient-centric care for hematological malignancies

Dr Dipty Patel-Donnelly from Virginia Cancer Specialists, Virginia, USA, led an educational session during ASH 2023, addressing the management of high-risk hematological malignancies in the community. The session covered acute leukemias, complicated lymphomas, multiple myeloma, and clinical research in the community. The speaker highlighted the unique challenges of acute leukemias and complicated lymphomas with case study examples, emphasising their rarity and acute presentation. The discussion covered the complexities of treatments and the coordination needed for transfusions. Despite challenges, advancements in novel therapies offer hope, but their application in the community setting requires overcoming logistical barriers. The significance of maintaining close communication, frequent patient visits, and a comprehensive care team, including social work and nutritionists, was a key highlight for managing these patients. Through a case example, the speaker also highlighted the limitations of available therapies and clinical trials in the community and how providing local access to innovative treatments can significantly improve patient outcomes. Dr Patel-Donnelly proposed a collaborative model between academic and community settings through accessing regional experts, early education programs, and co-management strategies to help improve patient outcomes, reduce costs, and increase engagement in clinical trials.

Dr Jesus Berdeja, Sarah Cannon Research Institute, Tennessee, USA, emphasised the importance of improving patient access, inclusion, and the overall complexity of care by decentralising advanced therapies and bringing them closer to patients in local clinics. Drawing insights from myeloma treatment experiences, the speaker highlighted the continuous and multi-faceted nature of the patient journey, which often requires a dynamic interplay between local and specialised clinics.

Access to advanced therapies, with a focus on CAR T and bispecific antibodies, was also a focus of the discussion. While CAR T shows great promise for hematological malignancies, it poses challenges related to patient selection, the necessity for bridging, and limited availability. On the other hand, bispecifics are considered more forgiving, with fewer logistical challenges, making them potentially suitable for older or frail patients. The speaker urged community practices to assess their capabilities for administering transplantation, CAR T and bispecifics and suggested internal referrals within practices and prompt consideration of administering bispecifics locally or through external referrals with the aim of bringing these advanced therapies closer to community patients.

Lastly, Dr Ruemu Birhiray, Hematology Oncology of Indiana, Indiana, USA, discussed the importance of diversity in clinical trials, particularly in the context of community-based practices. He highlighted disparities in care due to limited access to clinical trials, emphasising the challenges faced by patients who are unwilling or unable to travel to academic centers. Dr Birhiray presented a case of a patient who, despite having access to a clinical trial, opted for treatment locally due to caregiving responsibilities. The speaker addressed structural barriers, including the historical lack of diversity in clinical trials, and advocated for intentional efforts to improve inclusivity. Although acknowledging the National Cancer Institute initiatives to bring research to community practices, the current disparities in the availability of innovative therapies at community sites was pointed out. The need for individual responsibility among healthcare professionals to enroll diverse populations in clinical studies was stressed along with the need for a comprehensive and collaborative practice approach.

What does this mean for patients?

The discussions about community management at ASH 2023 promise positive shifts for patients with hematological malignancies, aiming for increased accessibility to advanced therapies like CAR T and bispecifics in local clinics. Collaborative care approaches recognise the ongoing nature of patient journeys, aiming for individualised treatments, inclusive clinical trials, and academic-community collaborations to provide more accessible and inclusive care, ultimately improving patient outcomes for all.

From HARMONY project

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients – Results from the HARMONY Big Data Platform 

A model providing individualized outcome estimations in adult AML patients with intensive treatment approaches was developed and validated. Predictions for relapse-free survival, cumulative incidence of relapse and overall survival were more accurate than those in the ELN2022 risk stratification. The model is accessible online via an interactive web calculator, and with further validation and refinement, it could be used in the future for clinical decision-making.

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

The evaluation of novel drugs in hemato-oncology is hampered by the relatively large sample sizes needed in RCTs. Supplementing trial data with external control data could overcome this obstacle. Our comparative study revealed that HARMONY Alliance data matched RCT data well for overall survival. Matched HARMONY Alliance data could therefore supplement prospectively collected control data in studies evaluating intensive therapy in elderly AML.

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A HARMONY Alliance Study

Acute promyelocytic leukemia (APL) is now curable in 75-90% of patients using targeted agents. RCTs revealed similar patient outcomes for chemotherapy and non-chemotherapy treatment regimens. However, the reliability of these outcomes was limited by the small patient cohorts used. Our long-term analysis using the larger HARMONY APL registry patient cohort revealed a significant survival advantage for the non-chemotherapy regimen with reduced early death rates and prolonged overall survival independent of Sanz risk score.

Other data published

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study – Autolus

Long-term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; pooled analysis of ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study) – Autolus

Delivery of Obecabtagene autoleucel (obe-cel, AUTO1) for the FELIX Pivotal Study Demonstrating Robust Cell Processing, Robust Release Testing, and Reliable Logistics, Together with Readiness for Sustainable Patient (pt) Care – Autolus

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial – Daiichi-Sankyo

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) – Daiichi – Sankyo

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 PhALLCON Study – Incyte

Use of ponatinib alone or combined with other therapies in relapsed/refractory Ph-like acute lymphoblastic leukemia. A  Campus ALL real-life study – Incyte

Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the GIMEMA ALL2820 trial – Incyte

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations – Janssen

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies – Orcabio

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide – Orcabio

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus – Orcabio

Molecular Measurable Residual Disease in Patients with Newly Diagnosed mIDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine – Servier

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH) – Servier

A Comparison of Acute Myeloid Leukemia Regimens: Hypomethylating Agents Combined With Ivosidenib or Venetoclax in Newly-diagnosed Patients With IDH1 Mutations: A Real-world Evidence Study – Servier

Trial in Progress: An Open Label Phase I/II, Multicentric Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 inhibitor Combined with AZA in Adults with Previously Untreated AML Ineligible for Intensive Treatment – Servier

Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 – Servier

Assessment of Outcomes of Consolidation Therapy by  Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-lineage Acute Lymphoblastic Leukemia: in the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial – Servier

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-cell Acute Lymphoblastic Leukemias – Servier

Minimal Residual Disease-Negative Complete Remission at the End of Induction is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy – Takeda

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial – Takeda

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed by Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia – Takeda

Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan – Takeda (study sponsored by Otsuka)